Midlife Alzheimer’s marker linked to later memory decline
Each standard-deviation increase in the midlife marker was linked to 0.030 standard deviations faster late-life memory decline during an 11-year follow-up.
Limit: The outcome was declining thinking skills, not dementia onset
An observational cohort analysis included 1,515 adults, 60.7% women and 25.5% Black, with blood samples collected at average ages 59.0 and 76.8 years. Researchers measured markers in stored samples and tracked memory, language and other thinking skills for 11 years after the later sampling.
Higher midlife levels of p-tau181, a modified tau protein marking Alzheimer’s disease-related changes, were associated with faster memory decline beginning 20 years later. Other midlife markers, reflecting amyloid proteins, nerve-cell damage and inflammation, were not associated with decline in any tested area. In later life, markers of Alzheimer’s disease changes, nerve-cell damage and inflammation were associated with faster decline in different thinking skills. Associations remained strongest for p-tau181 and memory. A standard deviation describes how widely measurements vary within a group.
Why it matters
The findings suggest a potentially long phase of cognitive decline that could precede dementia onset.
Caveats
This observational study cannot show that the blood markers caused cognitive decline. The reported outcome was declining thinking skills, not dementia onset.
The paper
Midlife and Late-Life Alzheimer Disease Blood Biomarkers and 11-Year Cognitive Decline
University of North Carolina School of Medicine
Neurology, 16 Oct 2026
